Successful outsourcing relationships for early phase analytics in drug development are driven by partnership.
Criteria for choosing an analytical services partner during the early phase of drug development include scientific skills/knowledge and resource availability, and the type of relationship developed with an analytical service provider is typically defined by customer needs. To start with, the provider of early phase analytical studies should show that they have the necessary scientific skills and knowledge to support the program in question. Discussions between client and provider are also necessary to ensure that both parties are comfortable with what is required out of the relationship.
Read this article in BioPharm International'sOutsourcing Resources 2018 eBook.
View other articles in BioPharm International's Outsourcing Resources 2018 eBook.
BioPharm International
eBook: Outsourcing Resources 2018
Vol. 31
March 2018
Pages: 27–29
When referring to this article, please cite it as F. Mirasol, " Choosing an Analytical Partner in Early Drug Development," BioPharm International Outsourcing Resources eBook (March 2018).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.